Jun 12, 00
|
| 10:12 ET |
ImmuLogic to Sell Shares of Cantab Pharmaceuticals Plc
|
|
Aug 25, 99
|
| 13:01 ET |
ImmuLogic Announces Stockholder Approval of Plan of Liquidation
|
|
Aug 18, 99
|
| 12:19 ET |
ImmuLogic Postpones Annual Meeting
|
|
Jul 15, 99
|
| 06:59 ET |
ImmuLogic Reports Second Quarter 1999 Financial Results
|
|
May 12, 99
|
| 16:01 ET |
ImmuLogic Reports First Quarter 1999 Financial Results
|
|
Apr 01, 99
|
| 07:01 ET |
ImmuLogic Announces Plans to Liquidate
|
|
Feb 17, 99
|
| 17:15 ET |
ImmuLogic Reports Fourth Quarter and Year-End 1998 Financial Results
|
|
Feb 08, 99
|
| 06:59 ET |
ImmuLogic Announces Intention to Distribute Assets to Shareholders
|
|
Dec 21, 98
|
| 02:30 ET |
Immulogic Announces Sales of Its Drugs of Addiction Vaccines Programs to Cantab Pharmaceuticals
|
|
Oct 26, 98
|
| 16:00 ET |
ImmuLogic Reports Third Quarter 1998 Financial Results
|
|
Jul 23, 98
|
| 16:15 ET |
ImmuLogic Reports Second Quarter 1998 Financial Results
|
|
Jul 20, 98
|
| 16:15 ET |
ImmuLogic Announces Manufacturing Collaboration with Chesapeake Biological Laboratories, Inc.
|
|
Jun 18, 98
|
| 17:15 ET |
ImmuLogic Announces Licensing Agreement with Heska Corporation
|
|
Jun 17, 98
|
| 16:01 ET |
ImmuLogic Promotes J. Joseph Marr, M.D. To Chief Executive Officer
|
|
May 26, 98
|
| 07:59 ET |
ImmuLogic Announces Licensing Agreement With Sankyo Co., Ltd.
|
|
Apr 21, 98
|
| 16:09 ET |
Immulogic Reports First Quarter 1998 Financial Results
|
|
Apr 16, 98
|
| 16:00 ET |
ImmuLogic Initiates Phase I Cocaine Vaccine Study
|
|
Feb 23, 98
|
| 16:17 ET |
ImmuLogic Reports Fourth Quarter And Year-End 1997 Financial Results
|
|
Dec 03, 97
|
| 17:15 ET |
ImmuLogic Receives Clearance for Cocaine Vaccine IND
|
|
Nov 24, 97
|
| 17:17 ET |
ImmuLogic Restructures Operations; ALLERVAX(R) Clinical Program on Hold
|
|
Oct 28, 97
|
| 15:53 ET |
ImmuLogic Reports Third Quarter 1997 Financial Results
|
|
Jul 30, 97
|
| 16:25 ET |
ImmuLogic Reports Second Quarter 1997 Financial Results
|
|
Jun 26, 97
|
| 16:09 ET |
ImmuLogic Delays ALLERVAX Ragweed Clinical Trial Program
|
|
Jun 17, 97
|
| 16:09 ET |
ImmuLogic Reduces Workforce as Part of its Focus on ALLERVAX Candidates
|
|
May 08, 97
|
| 16:02 ET |
ImmuLogic Receives SPIRCAP Grant from National Institute On Drug Abuse to Develop Cocaine Vaccine
|
|
Apr 29, 97
|
| 16:21 ET |
ImmuLogic Reports First Quarter 1997 Financial Results
|
|
Mar 05, 97
|
| 13:19 ET |
ImmuLogic Restructures Board Of Directors
|
|
Feb 10, 97
|
| 16:09 ET |
ImmuLogic Reports Fourth Quarter And Year-End 1996 Financial Results
|
|
Jan 27, 97
|
| 16:23 ET |
ImmuLogic Reports Positive Results From 1996 ALLERVAX RAGWEED Product Trial
|
|
Jan 06, 97
|
| 16:22 ET |
ImmuLogic Files Investigational New Drug Application with the FDA for Multiple Sclerosis Therapeutic
|
|
Dec 30, 96
|
| 16:55 ET |
ImmuLogic Updates Clinical Development Timeframe for ALLERVAX CAT Product Candidate
|
|
Dec 04, 96
|
| 16:31 ET |
ImmuLogic Announces Management Changes
|
|
Oct 29, 96
|
| 16:18 ET |
ImmuLogic Reports Third Quarter 1996 Financial Results
|
|
Oct 01, 96
|
| 09:19 ET |
ImmuLogic's Vaccine to Treat Cocaine Abuse Proves Effective in Animal Model of Addiction
|
|
Sep 12, 96
|
| 15:36 ET |
ImmuLogic Appoints Two New Members to Board of Directors and Hires Chief Strategic Officer
|
|
Aug 02, 96
|
| 15:24 ET |
ImmuLogic Awarded SBIR Grant to Develop Cocaine Vaccine
|
|
Jul 23, 96
|
| 08:47 ET |
ImmuLogic Appoints a New Executive Vice President of Research and a New General Counsel
|
|
Jul 22, 96
|
| 15:20 ET |
ImmuLogic Reports Second Quarter 1996 Financial Results
|
|
